Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Dose-finding Study to Determine if Oral BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in Elderly Subjects

Trial Profile

A Multicenter, Dose-finding Study to Determine if Oral BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in Elderly Subjects

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Dactolisib (Primary) ; Everolimus (Primary)
  • Indications Respiratory tract infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors resTORbio
  • Most Recent Events

    • 08 Nov 2018 Results presented in a resTORbio media release.
    • 08 Nov 2018 According to a resTORbio media release, data from the study will be presented The Gerontological Society of America 2018 Annual Scientific Meeting (GSA 2018).
    • 16 Oct 2018 According to a resTORbio media release, detailed results will be submitted for presentation at an upcoming medical meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top